We make anti-cancer T cells that hit the right target. Archer Tx is an early stage cell and gene therapy company, spun out of an academic lab at UC Berkeley. We're community funded with over $1million in support and are looking for partners to help advance our IND-enabling studies for our lead oligo oncology therapeutic.

The science: We can activate anti-cancer T cells in vivo using designer nucleic acid oligos. This proprietary technology (spun out of UC Berkeley) increases survival in melanoma models from 20% to 80%. We have 3 modalities; in vivo tumor infiltrating lymphocyte (TIL) activation, in vivo CAR T and ex vivo CAR T. We have extensive pre-clinical data in different oncology models and are now completing IND-enabling studies.